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ABSTRACT 
Surgical patients commonly experience postoperative, post-extubation 
hypoxia, which may require re-intubation. Endotracheal intubation and 
mechanical ventilation are associated with a number of complications, such as 
laryngotracheal injury, patient discomfort, ventilator-associated pneumonia and 
ventilator-associated lung injury. Avoiding reintubation postoperatively would 
help to prevent these complications in hypoxemic postoperative patients. 
There is some evidence that noninvasive ventilation, particularly 
continuous positive airway pressure (CPAP), is effective in treating postoperative 
hypoxemia. The Vapotherm 2000i (Vapotherm, Inc., Stevensville, MD) is anew, 
noninvasive device that delivers high-flow, warmed and humidified oxygen via 
nasal cannula in a way that mimics CPAP. Recent evidence supporting the use of 
CP AP in the treatment of postoperative hypoxemia suggests that V apotherm 
might also be effective in select postoperative patients, allowing them to avoid re-
intubation. The following paper includes a systematic review of the literature 
dealing with the use of noninvasive ventilation to treat postoperative hypoxemia, 
as well as the literature concerning the V apotherm 2000i. 
A research plan is described for a pilot study examining the safety and 
feasibility of using the V apotherm 2000i in relatively healthy adults with 
postoperative hypoxemia, in preparation for future studies of the effectiveness of 
this device in a broader population of postoperative patients. A discussion of 
issues involved in testing a new device follows. 
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INTRODUCTION 
Surgical patients conunonly experience postoperative, post-extubation 
hypoxia that, while generally transient, may require re-intubation. There is some 
evidence that noninvasive ventilation, particularly continuous positive airway 
pressure (CPAP), is effective in treating postoperative hypoxemia. The 
Vapotherm 2000i (Vapotherm, Inc., Stevensville, MD) is a new, noninvasive 
device that delivers high-flow, warmed and humidified oxygen via nasal cannula. 
While not a ventilator itself, the Vapotherm mimics CP AP in its mode of oxygen 
delivery. Recent evidence supporting the use of CP AP in the treatment of 
postoperative hypoxemia suggests that Vapotherm might also be effective in 
select postoperative patients, allowing them to avoid re-intubation. Because of its 
ability to warm and humidify, the Vapotherm can deliver oxygen at higher 
tolerable flow rates than CP AP. Additionally, the warming feature, unavailable 
with CP AP, allows the use of Vapotherm in the treatment of postoperative 
hypothermia. The ability to deliver flow rates of oxygen higher than those 
tolerable with CP AP, traditional nasal cannula or face mask could make the 
V apotherm a superior treatment for postoperative hypoxemia. This paper 
presents a systematic review of the literature to inform a research plan for a pilot 
study examining the feasibility of using the Vapotherm 2000i to decrease the rate 
of re-intubation among relatively healthy adult patients at UNC Hospitals who 
experience postoperative hypoxemia. 
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SYSTEMATIC REVIEW OF THE LITERATURE 
Methods for Literature Review 
A PubMed search was conducted March 31, 2005 using the search terms 
"noninvasive positive pressure ventilation" and "postoperative hypoxemia." It 
was limited to humans and included all years for which PubMed has data. This 
search returned only one result. A second search using the same limits and the 
search terms "noninvasive positive pressure ventilation" and "postoperative 
respiratory failure" returned 11 articles. The majority of articles addressed the 
use of noninvasive positive pressure ventilation (NIPPY) in patients with acute 
respiratory failure secondary to chronic disease, such as COPD or asthma. 
However, review of those papers and their reference lists revealed a number of 
articles regarding the use of NIPPY in patients with postoperative respiratory 
failure. References to abstracts alone were excluded. The search yielded a total 
of 5 articles, which are summarized in Table 1 in the Appendix. Another PubMed 
search using the term "V apotherm" returned 2 articles. One of those was an 
equipment investigation. The other is summarized in Table 2 in the Appendix. 
Additionally, 31 abstracts, published in the November, 2004 issue of 
Respiratory Care, were presented in December 2004 at the International 
Congress of the American Association for Respiratory Care. These abstracts 
were provided by personal communication with Kathleen Short, RRT, RN, 
Director of Respiratory Care at UNC Hospitals. Ten were related to Vapotherm. 
Of those, 7 were case reports and 3 were reports of equipment investigations. The 
case reports are summarized in Table 2 in the Appendix. 
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Results of Literature Review (see Appendix Tables 1 - 2) 
Postoperative Hypoxemia 
"Hypoxemia" can be defined by a number of measurements taken on room 
air, such as partial pressure of oxygen (P02)::;: 60 torr, arterial oxygen saturation 
(Sa02) ::;: 90%, or arterial partial pressure of oxygen I fraction of inspired oxygen 
ratio (Pa02/Fi02)::;: 200. The hypothesized explanations for postoperative 
hypoxemia include the loss of functional alveolar units due to atelectasis, as well 
as ventilation/perfusion mismatch.u Estimates of the incidence of postoperative 
hypoxemia vary, partly because more inclusive outcomes such as postoperative 
pulmonary complications may include a number of more specific processes such 
as atelectasis, pneumonia, and pulmonary embolism? The incidence of 
postoperative pulmonary complications has been estimated to be 5-1 0% among all 
surgical patients and 4-22% among abdominal surgical patients.3 Postoperative 
hypoxemia is estimated to occur in 30-50% of patients undergoing abdominal 
surgery and 8-1 0% of those patients may require intubation and mechanical 
ventilation.'· 2 Some authors distinguish between early postoperative arterial 
hypoxemia (EP AH), which occurs within hours after surgery, and late 
postoperative arterial hypoxemia (LP AH). Among all surgical patients, the 
incidence ofEPAH is 41-55%. The incidence ofLPAH is 41-50% among 
patients who have undergone major abdominal or thoracic surgery.4 
- 5 -
Complications of Intubation and Mechanical Ventilation 
Endotracheal intubation and mechanical ventilation are associated with a 
number of complications, such as laryngotracheal injury, patient discomfort, 
ventilator-associated pneumonia (V AP) and ventilator-associated lung injury 
(VALI).5· 7 VALl includes: I) barotrauma, which may lead to pneumothorax, 
pneumoperitoneum, or pneumomediastinum; 2) volutrauma, which may lead to 
pulmonary edema; 3) atelectrauma, and 4) biotrauma, which results in release of 
inflammatory mediators. 6 Thus, avoiding prolonged intubation or reintubation 
postoperatively would help to prevent these complications in hypoxemic 
postoperative patients. 
Noninvasive Positive Pressure Ventilation (NIPPV) 
A number of alternatives to intubation and mechanical ventilation exist. 
The International Consensus Conferences in Intensive Care Medicine defines the 
term noninvasive positive pressure ventilation (NIPPY) as "any form of 
ventilatory support applied without the use of an endotracheal tube. "8 This 
definition includes continuous positive airway pressure (CPAP), volume- and 
pressure-cycled systems, proportional assist ventilation (P A V), as well as the use 
of therapies such as helium-oxygen gas mixtures. 8 Extensive research has 
documented the effectiveness ofNIPPV in the treatment of acute respiratory 
failure (ARF) due to a number of causes, such as chronic obstructive pulmonary 
disease (COPD), asthma, and cardiogenic pulmonary edema.9 This literature is 
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reviewed by Hess (2004),9 Abou-Shala eta! (1996),10 Meyer and Hill (1994) 11 
and Evans (200Il 
Considering the evidence supporting the use ofNPPV to treat ARF 
resulting from chronic disease, it follows that NIPPY could be effective in the 
treatment of postoperative respiratory failure. Unfortunately, few studies have 
been conducted specifically looking at postoperative patients. The existing 
literature is reviewed below. 
Studies of NIPPV in Postoperative Patients 
Randomized Controlled Trials of Continuous Positive Airway Pressure 
(CPAP) 
A recent randomized controlled trial conducted in Italy1 supports the use 
ofNIPPV in postoperative respiratory failure. Squadrone eta!. (2005) 
randomized 209 postoperative patients to either a control treatment, oxygen via 
Venturi mask at an FiOz of 0.5, or the intervention, oxygen at an Fi02 of 0.5 plus 
CPAP at 7.5 em H20. The subjects were elective abdominal surgery patients who 
developed hypoxemia in the postoperative period, defined by a Pa02/Fi02 ratio 
less than 300 after extubation and a one-hour screening test breathing 
supplemental oxygen through a Venturi mask at an FiOz of0.3. Thus, these 
authors drew an arterial blood gas (ABG) on each subject. 
Squadrone et al. defined extensive exclusion criteria for their study 
population (Appendix Table I), thus limiting their trial to relatively healthy 
patients without significant underlying cardiovascular or respiratory disease. 
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Specifically, patients with a history of asthma or COPD were excluded. The 
primary outcome in this trial was incidence of intubation. Secondary outcomes 
included length of stay in the ICU, length of hospital stay, and incidences of 
pneumonia, infection, sepsis and mortality. The trial showed that the rate of 
intubation was higher in the control group (10%) than in the CPAP group (1%) 
(p=0.005). In fact, the trial was stopped early because the efficacy of CP AP was 
superior to that of oxygen alone. Patients treated with CP AP also had lower 
incidences of pneumonia (RR 0.19; 95% CI 0.01-0.76), infection (RR 0.27; 95% 
CI 0.07-0.94) and sepsis (RR 0.22, 95% CI0.04-0.99), and spent less time in the 
intensive care unit (1.4 days compared to 2.6 days, p=0.09). 
The strengths ofthis study include the fact that it was a well-designed 
randomized, controlled, unblinded study with concealed allocation and well-
defined inclusion and exclusion criteria. Despite being conducted at several 
centers, differences in treatment by center were minimized by defining protocols 
for operative anesthesia, postoperative pain control and uniform delivery of 
CPAP. Analysis was conducted on the basis of intention-to-treat and subjects 
were followed throughout their hospital stay. Unfortunately, masking is nearly 
impossible in a study of this type where the treatment is visible and obvious. The 
internal validity of this study is strong. The external validity is limited for several 
reasons. First, the trial was conducted in Italy, where patients and procedures 
may differ from those in the United States. Second, the extensive exclusion 
criteria limit the applicability of the results to relatively healthy patients who have 
undergone elective abdominal procedures. Patients with co-morbid disease or 
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those who have other types of surgery may be at higher risk for respiratory failure 
and CP AP may work differently in those patients. On the other hand, patients 
who undergo abdominal procedures may be at higher risk for respiratory failure 
d h . 1. . 12 ue to mec amca 1mpaument. 
Carlsson et al. 13 conducted a randomized controlled trial comparing 
supplemental oxygen by face mask with CP AP delivered by the same face mask 
as prophylactic treatment for pulmonary complications after abdominal surgery. 
They randomized twenty-four healthy patients undergoing elective open 
cholecystectomy to receive either pre-warmed, moistened oxygen at 30%, or 
CPAP with 30% pre-warmed, moistened oxygen. None of the patients had 
underlying lung disease. Outcome measures included pre- and post-operative 
measurements of arterial blood gases and vital capacity, as well as pre- and post-
operative chest x-rays. The investigator measuring vital capacity and collecting 
samples for ABG was not masked to treatment group as the treatment is visible. 
The investigator interpreting chest x-rays was, however, masked to treatment 
group. 
Carlsson et a!. found that 3 out of 13 patients in the CP AP group and 1 out 
of 11 patients in the comparison group had changes in their chest x-rays. Patients 
in the CPAP group showed an average of 44% decrease in vital capacity after 
surgery, while the control group had an average decrease of38%. After surgery, 
Pa02 values were slightly higher in the CP AP group. While the authors do not 
give specific values, they state that none of these differences between groups were 
statistically significant. 
-9-
There are a number of problems with this trial. First, the sample size is 
small. Second, the only inclusion criterion was having undergone elective open 
cholecystectomy. Third, the authors state that none of the patients had known 
lung disease, but they do not define any other exclusion criteria. Fourth, no 
statistical values are given. Finally, subjects were only followed through 24 hours 
after surgery. Adverse outcomes which can occur after 24 hours postoperatively 
and which may be related to intubation and mechanical ventilation, such as 
pneumonia, are not discussed. 
Stock et al. 14 conducted a small randomized study comparing three modes 
of respiratory therapy in postoperative patients: CP AP by face mask, incentive 
spirometry (IS) and cough/deep breathing (CDB). They randomized 38 adults 
scheduled for elective cardiac surgery to one of the three treatments. Therapy was 
started 2 hours after extubation. Outcomes included postoperative functional 
residual capacity (FRC), forced vital capacity (FVC), forced expiratory volume in 
one second (FEV 1), FEV 1/FVC ratio, chest x-ray and body temperature. Lung 
function tests were conducted 2, 24, 48 and 72 hours after extubation. Chest x-
rays were taken 24 and 72 hours postoperatively. Body temperature was 
measured every 6 hours for 72 hours after surgery. 
The results showed no differences between any of the groups in mean 
FRC, FVC, FEV~o or FEV1/FVC. There also were no differences in x-ray 
evidence of atelectasis, Pa02, PaC02, arterial pH, or in the incidence of body 
temperature above 38.5°C (an indication of possible pneumonia). 
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This study had a small sample size and poorly defined inclusion and 
exclusion criteria. The authors do not address whether investigators were masked 
to treatment, but the absence of masking is likely since it is difficult to mask an 
investigator when respiratory therapies are involved. Subjects were followed for 
72 hours after extubation. Follow-up throughout the hospital stay may have 
provided more data regarding late outcomes related to intubation and mechanical 
ventilation, such as pneumonia. One possible explanation of the findings in this 
study is that the patients were treated prophylactically, instead of after the 
development of hypoxemia or respiratory failure. It is possible that one or more 
of these modes oftherapy might be more effective in patients who have already 
developed respiratory difficulty. 
Case Series of CP AP 
Dehaven et al. 15 report a case series in which they treated 27 patients with 
postoperative hypoxemia with CPAP via face mask at an FI02 of0.45. All of the 
patients came from the general surgery service and had undergone major thoracic 
or abdominal surgery either electively or for trauma. They all developed post-
extubation hypoxemia that was resistant to chest physical therapy, incentive 
spirometry and continuous high-flow oxygen by face mask. Criteria for exclusion 
in the series included recent esophageal or gastric anatomoses, basilar skull 
fracture, laryngeal injury, and severe maxillofacial injury. Outcomes measures 
were pre- and post-treatment arterial blood gases, respiratory rate, heart rate and 
- 11 -
mean arterial blood pressure, as well as duration of treatment and incidence of 
intubation. 
The authors report that Pa02, Pa0z/FI02, and respiratory rate improved 
significantly in all patients after initiation of treatment (p<0.0005). Heart rate and 
mean arterial blood pressure did not change significantly after treatment. The 
mean duration of treatment with CPAP was 23 hours. Two of27 patients 
required intubation: one for excessive secretions and one for Pseudomonas 
pneumonia. 
One of the strengths of this study is that patients served as their own 
controls since arterial blood gases, respiratory rate and heart rate were measured 
prior to initiation of treatment. Nevertheless, the lack of a traditional control 
group limits the interpretation of the results. The authors describe some inclusion 
and exclusion criteria, but they do not mention the health status of the subjects 
prior to surgery. The patients in their sample may have been healthier or sicker 
than patients in other studies, which may have contributed to their finding of 
significant improvement in oxygenation after treatment with CP AP. Another 
problem with the internal validity ofthis study is that the authors do not describe 
how subjects were selected for inclusion in the study from among all general 
surgery patients. They mention that the included patients were enrolled over an 
18-month period and that they represent 8% of all patients extubated during that 
period. The authors do not state that the subjects were consecutive patients or 
identifY who selected them for inclusion. Finally, the authors state that the mean 
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duration of treatment was 23 ± 14 hours, but they do not define total follow-up 
time. 
Another case series is reported by Smith et a!. (1980). 16 These 
investigators treated with CPAP by face mask 44 patients with mild-to-moderate 
acute respiratory insufficiency. Subjects were both postoperative and trauma 
patients. Inclusion criteria included acute respiratory insufficiency and 
progressive deterioration of arterial oxygenation that was resistant to oxygen 
therapy, coughing, deep breathing and chest physical therapy. Patients had to be 
awake, cooperative and breathing spontaneously. They also had to be either 
normo- or hypocapnic, have stable cardiovascular status, and demonstrate a 
Pa02/FI02 ratio less than 300. Exclusion criteria are not described. Outcomes 
were pre- and post treatment arterial blood gases and respiratory rate, as well as 
incidence of intubation. 
All patients showed an increase in PaOz after treatment with CP AP. The 
mean Pa02/FI02 ratio increased from 171 ± 42 to 300 ± 68. One patient was 
intubated after developing respiratory academia. There were no significant 
changes in arterial pH or respiratory rate 
This study included both postoperative and trauma patients and, 
unfortunately, the authors do not mention how many were postoperative, which 
limits the applicability of this study to patients with postoperative hypoxemia. 
There is significant potential for selection bias as the authors do not describe the 
process of selecting subjects for inclusion in the series, nor do they describe 
exclusion criteria or duration of follow-up. 
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Studies of Vapotherm (please see Appendix for a picture of the device) 
The Vapotherm 2000i is neither a ventilator nor a CPAP machine, but its 
mechanism of oxygen delivery mimics CP AP. Other devices cannot deliver 
oxygen or air at rates above 6 liters per minute (lpm) because such high flow is 
uncomfortable for the patient, dries out the airway, and can damage the airway 
epithelia. 17 The Vapotherm 2000i, on the other hand, can safely and comfortably 
deliver gases up to 50 lpm. In addition to providing high flow, the Vapotherm 
2000i is capable of humidifying and warming the delivered gases up to 100% 
humidity and above body temperature. These characteristics of the device allow 
its use in the treatment of a variety of disease processes. 
High flow optimizes gas exchange and reduces work of breathing in 
chronic lung disease, such as COPD, while humidity and warmth improve 
oxygenation in conditions such as croup, asthma, and cystic fibrosis. The 
Vapotherm is able to deliver warm air directly to the body core, which is valuable 
in the treatment of hypothermia. Based on these attributes, the device has 
potential as a treatment for postoperative hypoxemia. A number of abstracts and 
case reports have been published about the benefits of the Vapotherm in various 
settings. However, the role of the Vapotherm is still being explored and no large 
trials have been conducted. 
One published pilot study examined the feasibility of using the V apotherm 
MT-3000 to treat radiation-induced xerostomia. Criswell and Sinha18 randomized 
8 patients to the standard treatment for xerostomia, a bedside cool air 
humidification system, or hyperthermic, supersaturated humidification via nasal 
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cannula from the Vapotherm MT -3000. After 2 weeks on the devices, subjects 
underwent a 1-week washout period and then crossed over to the other device for 
a 2-week treatment trial. Outcomes included objective assessment of xerostomia 
symptoms by physical exam, as well as patient-reported subjective assessment of 
symptoms using the Walizer Mouth Dryness Questionnaire. The authors found 
no significant differences between the two devices. The relevance of this study to 
the use of the Vapotherm in postoperative hypoxemia is limited for several 
reasons. First, the Criswell study used a different model ofVapotherm. Second, 
their study was very small and dealt with a different disease process. Third, the 
devices were being operated at home by patients, as opposed to being used in a 
more controlled setting and operated by trained personnel. Finally, the authors 
report that adherence to the study protocol was poor. Nevertheless, Criswell and 
Sinha do not report any adverse events resulting from use of the V apotherm, other 
than dislike of the device's noise and "being tethered to the nasal cannula." 
A number of abstracts and case reports describe the benefits of V apotherm 
in various settings. The first case series19 describes four patients treated with 
Vapotherm. The patients included: 1) a 16 month-old with respiratory distress 
secondary to pneumonia who would not tolerate an oxygen mask; 2) a 14 year-old 
with respiratory distress due to severe asthma for whom standard treatment with 
Albuterol was ineffective; 3) a 3 month-old extubated after cardiac surgery who 
developed severe atelectasis; and 4) a 2 Y:. year-old with respiratory synctial virus 
(RSV) and bronchiolitis who was initially treated with BiPAP but could not 
expectorate because of the mask. The goal for each patient was treatment of their 
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respiratory distress while avoiding intubation. All patients showed improved 
markers of respiratory distress (heart rate, respiratory rate, and Sa02), as well as 
improved comfort and decreased work of breathing. No patient required 
intubation. 
The second abstract comes from investigators in the UNC Hospitals Bum 
Unit.2° Cairns et al. describe the case of a 12 month-old female with 8% 
cutaneous burns and inhalation injury who developed respiratory distress after 
extubation. In order to avoid re-intubation, she was placed on Vapotherm 
delivering 50% oxygen at 15 lpm. Her heart rate, respiratory rate and breath 
sounds improved rapidly, as did her sedation requirements. She was weaned to 
room air over five days and discharged. 
Martinez-Gomez and Lefkowit~1 state that Vapotherm is used in the 
neonatal intensive care unit (NICU) at Wilford Hall Medical Center. They report 
the case of a 3 month-old former 25-week infant who developed respiratory 
distress after extubation. Multiple therapies were initiated, including blow-by, 
hood, mask CPAP and standard CPAP, but none was successful andre-intubation 
was considered. The infant was found to have significant swelling, as well as a 
vocal cord granuloma, resulting in an airway only 1 x2 mm wide. Vapotherm 
treatment was initiated with 100% oxygen at 6 lpm. The infant remained 
extubated and, at the time of publication, had been extubated for one month and 
was on standard nasal cannula ready for discharge. 
Manning et al.22 report the use ofVapotherm in a 64 year-old male with a 
history of COPD and stage III large cell carcinoma who developed pulmonary 
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edema, dyspnea, increased SaOz, and high respiratory rate on post -operative day 3 
after a left pneumonectomy. His respiratory distress did not improve on a double-
aerosol mask, nor on a non-rebreather mask with nasal cannula in series at 6 lpm. 
The patient was placed on Vapotherm nasal cannula with 100% oxygen at 20 lpm 
and subsequently developed improved oxygen saturation. He remained extubated 
and was later weaned to nasal cannula at 3 lpm. 
Sanchez and Sabato (2004i3 present the successful use ofVapotherm in a 
series of seven neonates with respiratory failure who were failing treatment with 
nasal continuous positive airway pressure (nCP AP). These authors report 
commonly using nCPAP in neonates at their institution and describe the 
complications associated with the therapy, including nasal septal trauma and the 
need for sedation. Infants entered in their trial were failing nCP AP, defined by at 
least one of the following criteria: 1) SPOz < 88 despite nCP AP > 8 em H20 on 
Fi02 > 0.60; 2) agitation believed to be caused by the nCPAP device and 
requiring increased sedation; 3) unacceptable work of breathing while on nCPAP; 
or 4) nasal trauma or breakdown. All patients were started on Fi02 of 0.60 at 5 
lpm. Flow was then adjusted based on work of breathing and respiratory rate. 
Fi02 was weaned to maintain the Sp02 between 88-96%. 
The authors found that 7 neonates, ranging in gestational age from 26-3 8 
weeks (all but one premature), required decreased FiOz and less sedation, and 
showed decreased PaC02• The authors report that the Vapotherm nasal cannula 
was not associated with nasal trauma. They also report one 710 gram infant who 
failed V apotherm treatment, but did well with nCP AP. 
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Hewitt eta!. (2004i4 report the use ofVapotherm to rewarm a previously 
healthy 50 year-old male construction worker who, in January of2004, fell20-25 
feet into a ditch where he then lay for approximately 2 hours in 40-45 degree 
water. Upon arrival in the Emergency Department, a Foley catheter probe 
revealed his body temperature to be 95°F. The patient was treated with a Bair 
Hugger warming device and warmed IV fluids. However, after 1 hour, his 
temperature had only risen to 95.8°. He was then placed on the Vapotherm 
delivering 30 lpm at an Fi02 of 21% and heated to 102°, keeping the Bair Hugger 
in place. Warmed IV fluids were discontinued. After 45 minutes, the patient's 
body temperature had increased to 98.1 °. Throughout treatment, the patient did 
not complain of discomfort from the warmed, high flow gas. He was treated with 
Vapotherm for 2 hours and was discharged 3 days later following work-up and 
observation for his injuries. 
Brennan et a!. (2004 i 5 report using Vapotherm as an alternative to nCP AP 
in the treatment of obstructive sleep apnea and nocturnal oxygen desaturation in 
an obese 52 year-old male with a BMI of 50.3 and a history of noncompliance 
with nCP AP. The patient was placed on the V apotherm nasal cannula at 40 lpm 
35% blended Fi02, and 100% relative humidity. During 7.5 hours overnight, the 
patient had an average Sa02 of 96% and his SaOz was greater than 90% during 
99% of the time for which data was collected. He experienced 6 episodes of 
apnea and 28 episodes ofhypopnea. The patient reported being much more 
comfortable using the V apotherm system than with nCP AP. 
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Equipment Investigations 
Waugh and Granger6 conducted an equipment investigation comparing 
the temperature and relative humidity of gases delivered by two nasal 
cannula/humidifier devices -the Vapotherm 2000i and the Salter Labs (Salter 
Labs, Arvin, CA) non-heated nasal cannula and bubble humidifier. Humidity and 
temperature measurements were collected by a digital psychrometer from each 
unit set at 5, 10 and 15lpm. They found that the Vapotherm 2000i delivered 
gases at 99.9% relative humidity at 3 7°C and the Salter Labs device delivered 
gases between 72.5 - 78.7% relative humidity at room temperature. The Salter 
Labs device does not have a heating mechanism and therefore delivers gases at 
ambient temperature. Waugh and Granger concluded that both devices meet the 
equipment humidification standards set by the American Association for 
Respiratory Care and both are acceptable options for high-flow oxygen therapy. 
Several abstracts have been published describing various equipment 
investigations involving Vapotherm. Walsh (2004i6 attached the Neopuff 
system, used to deliver controlled flow and pressure to infants, to the Vapotherm 
system in order to warm and humidifY the air delivered by the Neopuff. He found 
that combining the systems allowed warming and humidification of gases, 
without interfering with the Neopuff s function. 
Polston (2004i7 used the Vapotherm to deliver Heliox, a mixture of 70% 
helium and 30% oxygen, and found that attaching the Vapotherm did not affect 
Heliox tank life but allowed delivery of the gases at body temperature and 
saturated humidity. Newhart (2004i8 experimented with combining Vapotherm 
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with the Datex-Ohmeda INOvent, a device used to deliver inhaled nitric oxide 
and used for patients with pulmonary hypertension and refractory hypoxemia. He 
found that addition of the Vapotherm did not interfere with INOvent function at 
flow rates up to 30 lpm. Newhart suggests that higher flow rates or smaller 
cannulas could lead to excessive pressure in the INOvent system. 
RESEARCH PLAN 
There is strong evidence supporting the use of noninvasive ventilation in 
the treatment of acute respiratory failure due to chronic disease, but there are 
limited data regarding its use to treat postoperative hypoxemia. Vapotherm is a 
mode of noninvasive ventilation similar to CPAP, but because it is so new, there 
is little data supporting its use in any form of respiratory failure. However, 
considering that CP AP and other forms of NIPPY are effective at treating hypoxia 
related to complex chronic diseases, which involve multiple mechanisms of 
respiratory compromise, it seems logical that NIPPY might be effective for 
treating postoperative respiratory failure, which is usually due to transient 
processes such as airway compromise and/or atelectasis. There is some evidence 
that this is true, particularly the recent study by Squadrone et a!., which showed 
that CP AP reduced the rate of re-intubation in postoperative patients. The 
Vapotherm 2000i delivers high-flow, warmed and humidified oxygen non-
invasively in a way that mimics CP AP and involves only a nasal or trans-tracheal 
cannula. The proposed study seeks to test the safety and feasibility of using the 
V apotherm 2000i in relatively healthy adults with postoperative hypoxemia, in 
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preparation for future studies of the effectiveness of this device in a broader 
population of postoperative patients. 
Research Design 
Patient Population 
Sample Size 
The target sample size for this study will be 90 subjects. This is based on 
a calculation seeking to achieve a confidence level of 95% and 90% power to 
detect a 4% difference in oxygen saturation. Using a goal of 95% confidence and 
80% power, the sample size would be 68 subjects. 
Inclusion Criteria 
Criteria for emollment in this study will include postoperative, post-
extubation respiratory distress, defined by an Sa02 < 94% on room air, measured 
by pulse oximetry. Subjects will be between the ages of 18 and 80 and will have 
undergone general anesthesia. There will not be a protocol for induction and 
maintenance of anesthesia. Rather, the type of anesthesia will be at the discretion 
of the anesthesiologist. Patients will have undergone elective (non-emergency) 
surgery and will come from the following services: general surgery, orthopedics, 
gynecological, urological and plastic surgery. 
Exclusion Criteria 
Criteria for exclusion from the study will include: 1) chronic respiratory 
disease such as COPD or asthma; 2) Sleep disorders such as obstructive sleep 
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apnea; 3) sepsis and/or preoperative infection; 4) BMI > 40; 5) tracheostomy; 6) 
trauma to the face or neck; 7) chest wall abnormalities; 8) history of congestive 
heart failure, unstable angina, syncope or myocardial infarction within the 
previous 6 months; 9) emergency surgery; and 1 0) other conditions identified 
during the preoperative evaluation that are believed to be potentially life-
threatening or capable of causing respiratory failure. 
Recruitment and Consent 
The Department of Anesthesiology at UNC conducts preoperative 
evaluations on all inpatient surgical patients, as well as high-risk outpatient 
surgical patients. Lower risk patients who are not in-house are evaluated by their 
surgeon. In order to recruit patients who meet inclusion and exclusion criteria, 
surgeons from the general surgery, orthopedics, gynecological, urological and 
plastic surgery services will be asked to recommend eligible patients for the study 
during preoperative visits. At the conclusion of the visit, a trained research 
assistant will ask if the patient is interested in participating in the study. If so, the 
patient will be screened for eligibility based on the inclusion and exclusion 
criteria described above. Eligible subjects will be consented and enrolled. 
Intervention 
Postoperative patients will have an initial arterial oxygen saturation (Sa02) 
measured on room air and then continuously monitored during their stay in the 
post-anesthesia care unit (P ACU). Patients whose Sa02 falls below 94% at any 
-22-
time during their stay in the P ACU will be randomized to either the intervention, 
oxygen via the Vapotherm 2000i, or the control treatment, standard oxygen 
therapy via nasal cannula at 2 lpm, which corresponds to an Fi02 between 28-
30%. The primary difference between these two therapies is that the Vapotherm 
device delivers warmed, humidified gases at higher flow rates. All patients will 
be followed throughout their hospital stay in order to monitor re-intubation and 
other outcome measures. 
Criteria for Intubation 
Patients will be intubated and mechanically ventilated if, at any time 
during the study, intubation is clinically indicated for one or more of the 
following reasons: I) airway protection (in the case of seizure, coma, etc.); 2) 
management of secretions; 3) hemodynamic instability; 4) the patient is expected 
to require long-term ventilatory support, such as in the development of ARDS; or 
5) other emergent conditions judged by the P ACU team to indicate intubation. 
Outcome Measures 
The primary outcome measures will be the change in Sa02 measured by 
pulse oximetry and the incidence of re-intubation. Secondary outcomes will 
include ICU stay length (if applicable), hospital stay length, and incidences of 
pneumonia, infection, sepsis and mortality. Adverse events will be documented 
for both groups. 
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Statistical Analysis 
The sample size calculation was done using the "rule ofthumb" for 
sample size calculation for studies about means in two groups described by 
Dawson and Trapp.29 In this calculation based on a 95% confidence level, the 
ratio of the standard deviation to the difference to be detected (a I J.Lt - J.12) is 
squared and multiplied by a number corresponding to the desired power of the 
study. For a study with 90% power, the multiplier is 20 and for 90% it is 15. 
Based on the oxyhemoglobin dissociation curve, the desired clinically significant 
difference in oxygen saturation was 4%. The standard deviation for Sa02 used 
was 6%.30 
Patient demographic variables and outcome variables will be analyzed as 
depicted in Tables 1 and 2 below. Differences in demographic variables between 
groups will be analyzed by comparing means and standard deviations for age, and 
by percentages of the total for gender, smoking status, body mass index, ASA 
physical status and surgical service. The outcome variables will be analyzed for 
differences between the control (02 via nasal cannula) and intervention 
(Vapotherm) using t-tests and 95% confidence intervals. 
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Results 
Table 1 Patient Demographics 
Patient Variable Vapotherm 02 via nasal cannula 
Age (years; mean+ SD) 
Gender(%) 
Male 
Female 
Smoking Status (N, %) 
Body Mass Index (mean+ SD) 
ASA Physical Status(%) 
I 
II 
III 
IV 
Surgical Service (N, %) 
General 
Gynecology 
Orthopedic 
Plastic 
Urology 
Table 2 Outcome Measures 
Outcome Vapotherm 0 2 via nasal cannula 
Change in SaOz (%) 
Incidence ofre-intubation (N, %) 
ICU stay length (days) 
Hospital stay length (days) 
Incidence of pneumonia (N, %) 
Incidence of infection (N, %) 
Mortality (N, %) 
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DISCUSSION 
This study will examine the feasibility and effectiveness of the V apotherm 
device, compared with standard oxygen therapy via nasal cannula, at treating 
postoperative hypoxemia and preventing re-intubation in relatively healthy 
surgical patients. The proposed study will track more outcomes than previous 
investigations, ranging from oxygen saturation measured by pulse oximetry to 
mortality, and will follow subjects for adverse events until they are discharged 
from the hospital. While there is limited evidence supporting the use of the 
Vapotherm in specific settings, it is FDA-approved and is very similar to standard 
oxygen therapy via nasal cannula. The main difference is that the V apotherm is 
able to warm and humidify gases, which allows increased flow rates. 
In any investigation of a new device there is the possibility of equipment 
failure. In the case of the V apotherm, there are three ways that the device might 
fail. These include failure of the warming mechanism, failure ofthe 
humidification mechanism, and disconnection or failure of the oxygen delivery 
system. Oxygen delivery by standard nasal cannula is limited to 6 lpm, as higher 
flow rates can cause drying and cooling of the airway.31 The Vapotherm, on the 
other hand, can comfortably deliver up to 40 lpm. 17 Should the warming or 
humidification mechanism fail, the patient would be exposed to oxygen delivered 
at a high flow rate, which could result in discomfort from drying of the airway 
and could damage airway epithelia. While this would be unpleasant, it is not life-
threatening. If the oxygen delivery system were to fail, the patient would be 
transiently deprived of supplemental oxygen, which could be life-threatening. 
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However, this complication is equally likely with other forms of NIPPY, 
including nasal cannula and face mask. Additionally, like all postoperative 
patients, the subjects in this study will be closely monitored by the PACU staff. 
They will be cared for by a nurse or resident with experience caring for 
postoperative patients and their oxygen saturation will be monitored constantly 
until discharge from the PACU. 
Several additional safety measures are built into the study design. First, a 
protocol will be in place which specifically defines criteria for re-intubation so 
that any patient may be intubated if the physician believes that the subject's 
respiratory status is compromised. Second, the selection of94% as the cut-off 
Sa02 maximizes patient safety by identifYing early those patients at risk of 
progressing to severe hypoxemia. Most clinicians consider an Sa02 less than 
90% to indicate hypoxemia. This level of hemoglobin saturation corresponds to 
an arterial P02 of 60 torr at normal body temperature and pH. The choice of an 
Sa02 of 90% or a P02 of 60 torr as the cut-off point is based on the 
oxyhemoglobin dissociation curve. This curve is influenced by numerous 
parameters, including body temperature, pH, PC02, and 2,3-DPG concentration. 
However, when those parameters are within the normal range, the curve is S-
shaped and flattens out at about 90% saturation. This means that above 90% 
hemoglobin saturation, very large increases in POz are required to make small 
changes in hemoglobin saturation. On the other hand, below 90%, the curve has a 
steep slope such that small changes in SaOz indicate larger changes in POz. This 
means that once a patient's Sa02 reaches 90%, they are in danger of rapidly 
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progressing to severe hypoxemia. Choosing 94%, where the curve is still 
relatively flat, as the cut-off for this study provides more safety for the subjects by 
catching at-risk patients before they reach the steep, rapidly falling part of the 
curve. 
The use of SaOz as the measure of oxygenation raises certain issues. 
Many studies of ventilation, such as that by Squadrone et al., use the Pa02/Fi02 
ratio or Pa02 as the outcome measure. This requires drawing an arterial blood 
sample for blood gas analysis. While this might be simple in patients who already 
have an arterial line in place for surgery, it would subject other patients to an 
additional, painful, invasive procedure that is accompanied by its own risks of 
infection and bleeding. Since the subjects for this study will be relatively healthy, 
they are less likely to need an arterial line for monitoring during surgery and 
would thus require an additional arterial puncture in the PACU. An arterial blood 
gas analysis would provide more data on oxygenation than an SaOz since it 
includes P02, PC02, pH and HC03-, but it is more invasive, while SaOz is a 
reliable, non-invasive measure of oxygenation. 
As with any study, the use of a measurement tool such SaOz introduces the 
possibility of inter-observer variability. The sensitivity and specificity of pulse 
oximetry are 98-100% and 52-67%, respectively, and depend on the particular 
model of pulse oximeter. Additionally, factors such as patient movement, low 
perfusion, and low signal strength can alter the reliability of pulse oximetry.32 
Despite these possible problems, pulse oximetry is the standard measure of 
arterial oxygenation in postoperative patients. 
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The validity ofthis study could potentially be threatened by selection bias. 
It is designed such that the surgeons initially recommend subjects for the study, 
rather than the anesthesiologists who will be taking care of the patients 
postoperatively and making decisions about oxygenation and the need for re-
intubation. This presents several issues. First, the surgeons are less invested in 
the study since its results are not related to their work or the way that they treat 
patients. Postoperative hypoxemia affects their patients, but it is the 
anesthesiology team that identifies and treats problems with oxygenation and 
ventilation in the postoperative period. As a result, surgeons will likely be less 
motivated to identify and recommend subjects than would an anesthesiologist. 
Second, because the surgeons are probably less familiar with the treatment of 
postoperative hypoxemia and with the Vapotherm in particular, they might be 
hesitant to enroll their patients in the study. This could lead to an overall small 
sample or to the recruitment of only the healthiest, lowest risk patients. Third, 
there might be a difference between surgeons from the different departments in 
how interested and motivated they are to recommend subjects. Motivating 
surgeons to identify and suggest potential subjects to the research assistant will be 
an important step in the start-up phase of this study. 
Selection bias could also be introduced by the physicians and nurses in the 
PACU. While a study team member will identify subjects eligible for the study 
based on Sa02, the ultimate decision about patient care lies with the P ACU staff. 
This presents the opportunity for those doctors and nurses to choose not to enroll 
patients based on their perception ofthe patient's status or their own familiarity 
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with the Vapotherm. For example, a team member might decide not to enroll a 
patient with a low Sa02 because he or she is not familiar with the Vapotherm 
device, is worried about the patient's respiratory status, or is more comfortable 
using a standard nasal cannula. Appropriate training regarding use of the 
V apotherm and the study protocol among the P ACU staff will be imperative for 
the success of this study. 
The proposed study seeks to determine the feasibility of the use of 
V apotherm in the treatment of postoperative hypoxemia. While there is little 
existing evidence supporting use of the Vapotherm in specific settings, there are 
abstracts reporting its successful use to treat various conditions, including 
environmental exposure-related hypothermia and respiratory distress secondary to 
infection, chronic disease, inhalation injury and postoperative atelectasis. These 
reports do not provide sufficient evidence to change current standards of care, nor 
will the proposed study. However, this feasibility investigation may help to 
further define the role of the Vapotherm, specifically in the treatment of 
postoperative hypoxemia. 
Should the results show a benefit of the Vapotherm among relatively 
healthy subjects with postoperative hypoxemia, future studies could evaluate its 
effectiveness among an expanded patient population at higher risk of 
postoperative respiratory distress, such as those with chronic lung diseases like 
COPD and asthma. Other studies might further investigate the use of the 
Vapotherm to treat acute respiratory failure secondary to chronic disease. There 
is good evidence supporting the use of CP AP in that setting and the V apotherm 
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may also have a role in the treatment of acute exacerbations of chronic respiratory 
illness. 
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Appendix 
Table 1. Studies of CPAP in Postoperative Patients 
Author Study Intervention Population Inclusion Criteria Exclusion Criteria Outcomes Main Results Statistical 
Type Significance 
[Squadrone RCT Control-02 209 patients sip Elective abdominal Age >80 or <18; NYHA functional I-rate of Rate of p- 0.005 
v, 2005 via Venturi elective surgery requiring class II, III or IV; valvular heart intubation. 2- intubation 
#I] mask at abdominal laparotomy and disease, h/o dilated cardiomyopathy; ICU stay length, higher in 
Fi0,~0.5. surgery from >90min. viscera implanted pace maker; unstable angina; hospital stay control group 
Intervention - Piedmont exposure. MI or cardiac surgery within 3 months; length, (I 0 patients, 
o, at FiO, ~o.5 Intensive Care Pa0,1Fi02 :::_300 hlo COPD, asthma, or sleep disorders; incidences of 10%) than in 
plus CPAP~7 .5 Units Network after extubation and pre-op infection, sepsis, or both; pneumonia, CPAP group 
cmH20 (Italy) !-hour screening test BMI<40; tracheostomy, infection, sepsis, (I patient, 
breathing through a facial/neck/chest wall abnormalities; and mortality 1%). 
Venturi mask at an required emergency surgery; undergone 
FiO, ~ 0.3. AAA repair, chemotherapy, or 
immunosuppressive therapy within 
previous 3 months; If pre-
randomization arterial pH <7.30 with 
arterial C02 >50mmHg; arterial 0 2 
sat.<80% on maximal Fi02; signs of 
acute MI; SBP<90mmHg under 
optimal fluid therapy; presence of 
criteria for ARDS; Hgb<7; serum 
albumin <3; creatinine>3.5; or 
Glasgow Coma Score<l2. 
------
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Table 1 cont . 
Author Study Type Intervention Population Inclusion Criteria Exclusion Outcomes Main Results Statistical 
Criteria Significance 
Carlsson RCT Face mask 24 healthy pts Elective open None described Pre- and post- 3/13 CPAP pts and No sig. difference 
c, 1981 CPAPv. undergoing elective cholecystectomy opABG, 1111 control pts had btwn groups in 
control. Both open chest x-ray, post-op x-ray incidence of x-ray 
groups received cholecystectomy with vital capacity changes. 44% t in changes, decrease 
30%pre- no known lung VC in CPAP group in VC, or increase 
warmed and disease and 38%t in VC in in Pa02. Authors 
moistened 0 2. control group. CPAP don't give 
pts. had slightly statistical values. 
higher i in Pa02 in 4 
hrs after surgery 
Stock MC, Case COB (cough& 38 adults s/p elective Adults s/p elective None described FRC,FVC, No difference No p values 
1984 series/cohort deep breathing), cardiac surgery cardiac surgery FEV~> between groups in given. 
IS (incentive FEV/FVC, mean FRC, FVC, 
spirometry) or chest x-ray, FEV~> FEV,IFVC, x-
face mask bodytermp. ray evidence of 
CPAP atelectasis, Pa02, 
PaC02, arterial pH, 
incidence of body 
temp. >38.5°C. 
Dehaven Case Face mask 27 post-op patients Postextubation Recent ABG,RR, 2 patients intubated P<O.OOOS for 
CB, 1985 series/cohort CPAP at from general surgery hypoxemia resistant esophageal or HR, mean (1 for excessive difference in pre-
FI02~0.45 service who had to chest PT, gastric arterial BP, secretions, 1 for and post-
undergone major incentive anastomoses, duration of Pseudomonas treatment, Pa02, 
thoracic or abdominal spirometry, and basilar skull treatment, pneumonia). Pa02 i Pa02/FI02, and 
surgery electively or continuous high- fracture, intubation in all pts. Pa02, RR 
for trauma flow 0 2 by face laryngeal injury, PaO,IFI02, RR 
mask severe improved in all pts. 
maxillofacial Mean treatment 
injury duration ~ 23 hrs. 
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Table 1 cont. 
Author Study Intervention Population Inclusion Criteria Exclusion Outcomes Main Results Statistical 
Type Criteria Si2nificance 
SmithRA, Case Face mask 44 trauma and post- ARI and progressive deterioration of None ABG, 1 pt intubated for P<0.005 for 
1980 series CPAP op pts w/ mild-mod. arterial oxygenation resistant to 0, described Pa02/FI02, acidemia, Pa02 j in all change in 
acute respiratory coughing, deep breathing, and chest PT. RR, pts. Pa02/FI02 j from Pa0z/FI02 
insufficiency ( ARI) Awake, cooperative, spontaneously intubation 171±42 to 300±68. 
breathing, norma- or hypocapnic, No significant change 
Pa02/FI02<300, stable cardiovascular in pHa or RR. 
status 
Table 2. Studies ofVapotberm 
Author Study Type Intervention Population Inclusion Exclusion Outcomes Main Results Statistical 
Criteria Criteria Si~nificance 
Criswell Randomized, Standard cool 8 ENT pts with h/o head /neck cancer Age :0: 18; Stating that Physical exam No significant n/a 
MA, controlled, air bedside capable of xerostomia using objective differences between 
2001 crossover humidification completing 3 was not a xerostomia scale; devices. 
pilot study system v. clinic visits; problem; life subjective 
hyperthermic, completion expectancy < assessment of 
supersaturated of:O: 5000 3 months; xerostomia 
humidification cGy external planned (Walizer Mouth 
via nasal beam radiotherapy, Dryness 
cannula radiation to chemotherapy Questionnaire); 
(Vapotherm oral cavity or surgery VAS measuring 
MT-3000) or during study; dryness, speaking 
oropharynx active disease and swallowing; 
:0:4 months limiting patient reports of 
before study ability to overall impression 
entry; participate. of devices. 
persistent, 
symptomatic 
radiation-
induced 
xerostomia. 
Frick J, Case Series NIPPY via Pt. A- 16 rnlo w/respiratory distress n/a n/a Intubation, No patient was n/a 
2004 Vapotherm 2° to pneumonia, would not tolerate 0 2 markers of intubated, all showed 
(abstract) mask. respiratory distress improved markers of 
Pt. B- 14 y/o w/ respiratory distress (HR, RR, 0 2 sat), respiratory distress, 
2 o severe asthma, baseline therapy comfort, work of improved comfort, 
(cont. Albuterol) ineffective. breathing decreased work of 
Pt. C - 3 m/o Post-op/post-extubation breathing. 
cardiac patient w/ severe atelectasis. 
Pt. D - 2.5 y/o w/ respiratory distress 
2° to RSV, bronchiolitis, unable to 
expectorate 2° to BPAP mask 
Table 2 cont 
Author Study Type Intervention Population Inclusion Exclusion Outcomes Main Results Statistical 
Criteria Criteria Significance 
Cairns B, Case Report NIPPY with 12 m/o female with 8% cutaneous n/a n/a intubation Patient was not re- n/a 
2004 Vapotherm burns and inhalation injury, developed intubated, weaned to 
(abstract) respiratory distress after extubation. room air after 5 days 
of treatment and 
discharged. 
Martinez- Case Report NIPPY with >3 m/o former 25-week twin failed n/a n/a intubation Patient remained n/a 
Gomez Vapotherm extubation to blow-by, hood, mask extubated. 
R, 2004 CPAP or standard CPAP and required ! 
(abstract) re-intubation. Vapotherm treatment 
started at 6 lpm and 1.0 Fi{},. Infant 
remained extubated. 
Manning Case Report NIPPY with 64 y/o male with b/o COPD, stage III n/a n/a intubation Patient was not n/a 
L, 2004 Vapotherm large cell carcinoma sip L intubated, weaned to 
(abstract) pneumonectomy, developed traditional NC 3 lpm 
pulmonary edema, dyspnea, decreased within 48 hours. 
Sa02, and high RR on post-op day 3, 
did not improve with double-flow 
aerosol mask or NRB mask with NC in 
series at 6 lpm. Patient placed on 
Vapotherm NC 20 lpm,37°C, 100% 
Fi02 
Sanchez Case Series NIPPY with 7 neonates (26-38 weeks gestation) Failing n!a Fi02, sedation All required decreased n/a 
F,2004 Vapotherm with respiratory failure who failed therapy with requirements, Fi02, less sedation, and 
(abstract) standard treatment with nCPAP. nCPAP I ABG showed decreased 
PaC02• 
Hewitt Case Report NIPPY with 50 y/o previously healthy construction n/a n/a Body Body temperature n/a 
MJ,2004 Vapotherm worker who fell 20-25 feet into a ditch temperature increased from 95.8° to 
(abstract) and lay for 2 hours in 40-45° water, 98.1 o after 45 minutes. 
failed treatment with warmed IV fluids 
and Bair Hugger 
Brennan Case Report NIPPY with 52 y/o male with b/o OSA, BMI-50.3, n/a n/a Sa02, episodes Average Sa02-96%, 6 n!a 
T, 2004 Vapotherm noncompliant with nCPAP of apnea and episodes of apnea, 28 
(abstract) hypopnea episodes ofhypopnea . 
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Vapotherm 2000i 
